Document is current

Article History

Received: 20 February 2025

Revised: 21 March 2025

Accepted: 20 April 2025

First Online: 29 April 2025

Declarations

:

: Reviewed and approved by Mount Sinai School of Medicine Institutional Review Board; STUDY-24-01072.

: This study was approved by the Mount Sinai School of Medicine Institutional Review Board for a waiver of informed consent based on study protocol. The patients in this manuscript have given written informed consent to publication of their case details.

: Authors Stratman, Amara, Tan, George-Washburn, Shokrian, and Lau have no conflicts to disclose. Author Khattri has received research funds on behalf of Mount Sinai from: BMS, Incyte, Takeda, Astrazeneca and is a speaker for Lilly, UCB, Abbvie, Janssen, Regeneron, and Arcutis. Author Lebwohl has received research funds on behalf of Mount Sinai from: AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB, Inc., and is a consultant for Almirall, AltruBio Inc., AnaptysBio, Apogee, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, EPI, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. Author Guttman-Yassky is an employee of Mount Sinai and has received research grants (paid to the institution) from Boehringer Ingelheim, Leo Pharma, Pfizer, Cara Therapeutics, UCB, Kyowa Kirin, RAPT, Amgen, GSK, Incyte, Sanofi, Bristol Meyers Squibb, Aslan, Regeneron, Anaptysbio, Concert, Janssen. Author Guttman-Yassky is a consultant for Abbvie, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics Limited, Artax Biopharma Inc., AstraZeneca, Bristol Meyers Squibb, Boerhinger-Ingelhiem, Cara Therapeutics, Centrexion Therapeutics Corporation, Connect Biopharm, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals, Inc., Fairmount Funds Management LLC, Forest Laboratories Galderma, Gate Bio, Google Ventures (GV), GSK Immunology, Horizon Therapeutics U.S.A., Inc., Incyte, Inmagene, Janssen Biotech, JT Central Pharmaceutical Research Institute, Jasper Therapeutics, Kyowa Kirin, Leo Pharma, Merck, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, NUMAB Therapeutics AG, OrbiMed AdvisorsLLC, OTSUKA, Pfizer, Pharmaxis Ltd, Pioneering Medicine VII, Inc., Proteologix US Inc, RAPT, Regeneron Pharmaceuticals, RibonTherapeutics, Inc., Sanofi, SATO, Schrödinger, Inc., Sun Pharma Advanced Research Company (SPARC), Teva Branded Pharmaceutical Products R&D, UCB.